Lipid nanoparticles (LNPs) now carry a wide range of cargo — long RNA, short oligonucleotides, plasmid DNA, proteins, peptides, CRISPR ribonucleoproteins, small molecules, and combinations of these — and each cargo leaves the particle under a different set of forces. A dialysis setup that cleanly resolves a hydrophilic small molecule can be almost blind to an mRNA strand held in the lipid core, while a sample-and-separate method tuned for a large ribonucleoprotein can distort the profile of a lipophilic drug. Because release behavior is payload-specific, in vitro release testing (IVRT) must be built around the cargo. This page maps each method to its payload class, explains what makes a profile meaningful, and shows where the recommended method changes between cargos.
An LNP is not a static container. Its lipid bilayer, ionizable lipid content, PEG shield, and internal aqueous core sit in a dynamic equilibrium with the surrounding medium, and the payload can migrate, leak, or stay locked in place depending on how that equilibrium is disturbed. LNP formulation sets the starting point, but only a release assay shows what happens to the cargo over time. Release testing turns the formulation into a measurable quantity: how much payload becomes available, and how fast. That is the difference between knowing a cargo is encapsulated and knowing it stays encapsulated long enough to matter.
Because release behavior is tied to structure, the assay usually runs alongside lipid nanoparticle characterization. Size, polydispersity, surface charge, and lipid composition explain why a profile looks the way it does, and they separate a genuine formulation change from an artifact of the test. Teams developing lipid nanoparticles for drug delivery use release as a decision tool: it ranks candidates, flags unstable compositions, and supports comparability when a process changes.
The central difficulty is that release is not one phenomenon. It is at least four, and each payload class feels them differently.
Electrostatic dissociation: nucleic acids are held by charge pairing to the ionizable lipid, so release depends on pH, ionic strength, and competition with other anions.
Partitioning and diffusion: small molecules move according to their own solubility and lipophilicity, largely independently of the lipid shell that LNP encapsulation created.
Disassembly of a structured complex: proteins, peptides, and ribonucleoproteins are released only when the internal assembly or the particle itself breaks down.
Coupled release: in co-loaded particles, two cargos can leave at different rates, and a total released mass hides that divergence.
The table below summarizes how the dominant mechanism, the recommended method family, and the main artifact shift across payload classes — the reason no single standardized release method fits every LNP.
Table 1. LNP Payload Classes — Release Drivers, Recommended Methods, and Common Artifacts
| Payload Class | Dominant Release Driver | Typical Profile Shape | Recommended Method Family | Main Methodological Risk |
| Long RNA (mRNA, saRNA, circRNA) | Electrostatic release from ionizable lipid; core disassembly | Slow, sustained, often incomplete within 24-48 h | Dialysis with dye-exclusion fluorescence readout | Membrane retains free RNA; incomplete release misread as stability |
| Short oligonucleotides (siRNA, miRNA, ASO) | Charge competition plus faster diffusion | Moderate rate, higher early fraction than long RNA | Sample-and-separate with size- or charge-based readout | Poor separation of free and bound species of similar size |
| Plasmid DNA | Electrostatic binding and steric entrapment of a large, rigid molecule | Very slow, frequently incomplete | Large-cut-off dialysis with agarose-gel or chromatographic readout | Shear and adsorption during separation distort results |
| Proteins and peptides | Dissociation plus surface desorption | Biphasic — surface-associated burst, then slow core release | Sample-and-separate with immunoassay or LC-MS readout | Surface adsorption to membrane and vessel walls |
| CRISPR ribonucleoprotein | Disassembly of a large multi-component complex | Delayed, complex-dependent, hard to resolve | Gentle dialysis with component-specific detection | Assay sensitivity to a large, fragile cargo |
| Lipophilic small molecules | Partitioning into the acceptor phase | Rapid burst followed by a slow tail | Dialysis with albumin or surfactant sink | Non-sink conditions suppress apparent release |
| Hydrophilic small molecules | Diffusion through aqueous channels | Fast, near-complete release | Sample-and-separate with early sampling | Early burst lost during sample handling |
Most LNP release work falls into three operational families: separation by a membrane, separation by a physical force, and continuous or real-time measurement. Each answers a slightly different question, and the choice sets the time resolution, the sensitivity to burst release, and the artifacts a scientist must correct for.
Table 2. Comparison of Core LNP In Vitro Release Testing Methods
| Method Family | Separation Principle | Time Resolution | Best Fit | Key Limitation |
| Dialysis and reverse dialysis | Passive diffusion across a membrane | Low; hours between points | Slow-release formulations; long-term stability signals | Membrane effect and non-sink accumulation |
| Sample-and-separate | Ultrafiltration, ultracentrifugation, or chromatography | High; discrete but flexible sampling | Fast screening of many candidates | Force applied can shift the equilibrium being measured |
| Continuous-flow and in situ | Flow-through cell or real-time detection | High; near-continuous | Leakage detection and mechanistic studies | Greater setup complexity and method-specific calibration |
Recommended IVRT method: passive dialysis across a size-selective membrane, with free payload quantified in the acceptor phase at defined time points.
Why it fits: dialysis places the LNP suspension inside a membrane bag or mini-dialyzer and lets free payload diffuse into a large acceptor volume. Reverse dialysis inverts the geometry: many small sample cells sit inside one large release medium, which keeps sink conditions easier to maintain. Both are gentle and well suited to long time courses, which is why they remain the default reference method for slow-release nucleic acid LNPs.
Key parameters: membrane molecular weight cut-off chosen well above payload size, large acceptor volume, gentle agitation, 37 °C, sampling across 24-72 h.
Watch out for: the membrane effect. Payload released from the particle still has to cross the membrane before it can be counted, so the measured profile is a convolution of release and diffusion; when the membrane is the slower step, the assay reports an artificially prolonged release time. Include a membrane-only control so the lag is quantified rather than argued about. Where the goal is to see how a formulation behaves under biologically relevant conditions, a dedicated nanoparticle in vitro evaluation program can pair dialysis with the right readout from the start.
Recommended IVRT method: centrifugal ultrafiltration, ultracentrifugation, or size-exclusion chromatography, with free payload measured in the filtrate or eluate.
Why it fits: sample-and-separate methods take an aliquot at each time point and physically remove the particles, measuring the free payload left behind. These approaches are fast and tolerate many parallel samples, which makes them the usual choice for early screening.
Key parameters: filter cut-off well below particle size, low centrifugal force when working with fragile payloads, immediate quench or separation after sampling, and a validated recovery control.
Watch out for: the separation step itself perturbs the system. High centrifugal force can compact or rupture particles, a filter can adsorb payload, and any delay between sampling and separation lets release continue. Run a spiked free-payload sample through the identical separation, so recovery and adsorption losses are measured rather than assumed. Efficiency testing such as encapsulation efficiency testing shares the same separation chemistry, and reusing that validated step keeps the two assays consistent.
Recommended IVRT method: a flow-through cell perfused with release medium, or an in situ fluorescence readout that reports the fraction of payload still associated with the particle.
Why it fits: continuous-flow systems place the formulation in a cell and perfuse release medium past it, sampling the effluent over time. In situ methods detect the payload without any separation step — for example, a fluorescent readout reporting the fraction still associated with the particle.
Key parameters: medium composition matched to the payload, flow rate set to keep sink conditions, detector calibrated against a known standard, and a time resolution in minutes rather than hours.
Watch out for: the medium must be tailored per payload, and the detector must be calibrated against a known standard, or the system reports relative change rather than concentration. Where release is triggered by an external stimulus, stimuli-responsive testing provides the matched design. Use it to characterize a rapid early release phase, support a mechanistic claim about a release trigger, or monitor leakage during storage.
BOC Sciences develops and optimizes in vitro release testing methods around the specific cargo, membrane, and release medium — so the profile you get reflects the formulation rather than the assay.
Nucleic acid payloads share a polyanionic backbone that binds tightly to the ionizable lipid, but they differ greatly in size, secondary structure, and stiffness — and those differences, not the nucleic acid label, decide the assay. The readout has to distinguish intact encapsulated strands from free strands, which usually means dye-exclusion fluorescence, anion exchange, or chromatography. The table below maps each nucleic acid payload to its recommended IVRT method.
Table 3. Recommended IVRT Methods for Nucleic Acid Payloads
| Nucleic Acid Payload | Recommended IVRT Method | Separation Principle | Key Parameters | Critical Control |
| Long RNA (mRNA, saRNA, circRNA) | Dialysis with dye-exclusion fluorescence readout | Passive diffusion across membrane; dye binds only free RNA | MWCO 300-1000 kDa, PBS or serum-containing medium, 37 °C, 24-72 h | Membrane-only control; orthogonal readout for partial release |
| Short oligonucleotides (siRNA, miRNA, ASO) | Sample-and-separate with size- or charge-based separation | Ultrafiltration or anion-exchange chromatography | 30 kDa filter cut-off, low-binding tubes, samples within the first minutes | Spiked recovery control; first sample before 5 min |
| Plasmid DNA | Gentle dialysis with large-cut-off membrane and gel-based readout | Passive diffusion across 1000 kDa membrane; agarose gel quantitation | MWCO ≥ 1000 kDa, low-shear handling, extended time course, integrity-preserving medium | Supercoiled-versus-nicked ratio by gel; free-DNA recovery control |
Recommended IVRT method: dialysis across a 300-1000 kDa membrane against phosphate-buffered saline or a serum-containing medium, with free RNA quantified by a dye-exclusion assay.
Why it fits: long RNA is the payload class where release is slowest and most method-sensitive. The strand is large, highly charged, and buried in the lipid core, so release depends on protonation of the ionizable lipid by H+ and on competition from anions in the medium. mRNA-loaded LNPs benefit from a dialysis design with a well-matched cut-off rather than from a force-based separation that would disrupt the particle.
Key parameters: MWCO 300-1000 kDa, PBS at pH 7.4 or a serum-containing medium for biological relevance, 37 °C, sampling at 1, 2, 4, 8, 24, and 48 h, and a large acceptor volume to keep sink conditions.
Watch out for: saRNA is longer and more structured, and circRNA resists exonuclease attack, so both show a smaller early-release fraction. Their programs, saRNA LNP delivery and circRNA LNP delivery, benefit from longer observation windows. Pair the dye-exclusion readout with an orthogonal separation, since a single fluorescence reading cannot tell partial release from aggregation. Broader RNA LNP delivery programs often standardize this pairing so profiles stay comparable.
Recommended IVRT method: sample-and-separate with size- or charge-based separation, taking the first sample within minutes to capture the burst.
Why it fits: short oligonucleotides are smaller and more mobile, so they leave the particle faster and are easier to separate from the carrier. The challenge shifts to resolution: free and encapsulated species can have similar charge and size, so a poorly chosen column or membrane reports a flat profile for every candidate.
Key parameters: ultrafiltration with a 30 kDa cut-off or anion-exchange chromatography, low-binding tubes, carrier protein in the collection vial, and samples at 1, 5, 15, 30, 60, and 120 min.
Watch out for: a fast early release that is real, not an artifact. Because these cargos diffuse quickly, a genuine burst can be missed if the first sample is taken too late. Anion-exchange and size-based separation work well for siRNA-loaded LNPs, and the same logic extends to miRNA LNP delivery and ASO LNP delivery.
Recommended IVRT method: gentle dialysis with a large-cut-off membrane (≥ 1000 kDa), with supercoiled-versus-nicked DNA tracked by agarose gel.
Why it fits: plasmid DNA is the least forgiving nucleic acid cargo to test. It is large and rigid, held by both charge and steric entrapment, so release is slow and frequently incomplete over a typical assay window. Force-based separations can damage the supercoiled structure and produce a misleading signal, which is why a low-shear dialysis design is preferred.
Key parameters: MWCO ≥ 1000 kDa, low-ionic-strength buffer, extended time course of 48-168 h, and a gel-based readout that distinguishes supercoiled from nicked or linear DNA at each time point.
Watch out for: do not report a kinetic model fitted to an incomplete curve; pDNA LNP delivery studies report the fraction released at defined time points instead. Gene delivery LNPs benefit from an assay that also tracks DNA integrity. The strategies for nucleic acid encapsulation in LNPs and nucleic acid encapsulation methods and strategies explain many release differences between plasmid and short-oligonucleotide formulations. For folded RNA cargos, conformation-sensitive LNPs for RNA therapeutics add a variable a release assay should not ignore.
From dye-exclusion fluorescence to anion-exchange separation, BOC Sciences builds readouts that resolve free RNA from intact encapsulated RNA across mRNA, saRNA, circRNA, siRNA, miRNA, and ASO cargos.
Biological cargos add a dimension nucleic acids do not have: the payload itself can unfold, aggregate, or stick to surfaces. Release testing here measures not only how much cargo leaves the particle, but whether it leaves in a usable form — which makes recovery controls and a structure-sensitive readout more important than raw sensitivity. The table below maps each biological payload to its recommended IVRT method.
Table 4. Recommended IVRT Methods for Protein, Peptide, and RNP Payloads
| Payload | Release Behavior | Recommended IVRT Method | Key Parameters | Suitable Readout | Critical Control |
| Proteins | Biphasic; surface-associated fraction releases early, core fraction slowly | Sample-and-separate with immunoassay readout | Low-binding tubes, carrier protein, low centrifugal force, samples at 0.5, 1, 2, 4, 8, 24 h | Immunoassay or labeled-protein fluorescence | Protein-free recovery control to detect adsorption |
| Peptides | Charge-dependent; small size accelerates diffusion | Sample-and-separate with LC-MS readout | Standard curve prepared in the actual release medium; samples within first 15 min | LC-MS or fluorescence | Standard curve in the actual release medium |
| CRISPR ribonucleoprotein | Delayed; requires disassembly of a multi-component complex | Gentle dialysis with component-specific detection | MWCO ≥ 1000 kDa, serum-free medium, parallel functional assay | Activity-based or component-specific detection | Complex integrity confirmation alongside release |
Recommended IVRT method: sample-and-separate with an immunoassay or labeled-protein readout, run in low-binding tubes with a carrier protein.
Why it fits: proteins partition between the particle core, the particle surface, and the surrounding medium, and only the last is the payload that matters for delivery. Protein encapsulation in LNPs produces a biphasic profile: a fast surface-associated fraction and a slow encapsulated fraction.
Key parameters: ultrafiltration with a cut-off well below particle size, low centrifugal force, samples at 0.5, 1, 2, 4, 8, and 24 h, and an immunoassay validated against a spiked sample.
Watch out for: use low-binding vessels and a carrier protein, otherwise release is underestimated because cargo is lost to plastic rather than retained by the particle. The considerations for LNP antigen delivery mirror those for therapeutic proteins, and programs developing LNP-based protein delivery typically validate the readout against a spiked sample in the same medium.
Recommended IVRT method: sample-and-separate with liquid chromatography-mass spectrometry or fluorescence detection, against a standard curve prepared in the same release medium.
Why it fits: peptides sit between small molecules and proteins: small enough to diffuse reasonably fast, but charged enough to interact strongly with the lipid shell. Release is therefore sensitive to pH and ionic strength. Peptide encapsulation in LNPs is assessed most cleanly with a chromatographic or mass-spectrometric readout that separates intact peptide from fragments.
Key parameters: acidic or neutral buffer chosen for peptide stability, sampling within the first 15 min, low-temperature handling for heat-sensitive sequences, and an internal standard spiked into every sample.
Watch out for: because the cargo is small, the membrane and separation step matter less than the medium. Programs focused on LNP-based peptide delivery usually fix the medium early and vary only the formulation.
Recommended IVRT method: gentle dialysis against a serum-free medium, paired with a parallel functional assay that measures complex activity.
Why it fits: a ribonucleoprotein is a large, multi-part assembly, and its release cannot be described by a single strand crossing a membrane. What matters is whether the complex leaves the particle intact and active. CRISPR RNP LNP delivery programs frequently pair a physical release measurement with a functional readout.
Key parameters: MWCO ≥ 1000 kDa, serum-free medium to keep the activity readout interpretable, parallel functional assay at each time point, and component-specific detection for the protein and the guide RNA separately.
Watch out for: RNP performance is often limited less by release than by escape from the endosome, so release data are read together with endosomal escape evaluation to avoid attributing an intracellular bottleneck to the release step.
Small molecules behave differently from biological cargos because release is driven largely by partitioning and solubility rather than charge pairing. That makes the choice of release medium unusually powerful: the same formulation can appear to release an entire dose in minutes or to retain it for days, depending on how favorably the medium solvates the drug. The table below maps each small-molecule class to its recommended IVRT method.
Table 5. Recommended IVRT Methods for Small-Molecule Payloads
| Payload Type | What Drives Release | Recommended IVRT Method | Key Parameters | Medium Consideration | Common Artifact |
| Hydrophobic small molecules | Partition coefficient and acceptor-phase capacity | Dialysis with albumin or surfactant sink | Albumin or cyclodextrin at a justified concentration, large acceptor volume, 37 °C | Requires a solubilizer or protein sink | Apparent slow release caused by non-sink conditions |
| Hydrophilic small molecules | Diffusion through aqueous channels | Sample-and-separate with early sampling | First sample within 1-5 min, low-binding tubes, validated HPLC or UV readout | Simple aqueous buffer is often sufficient | Burst phase lost before the first sample |
| Ionizable and charged small molecules | Ionization state and electrostatic interaction with the lipid | Dual-pH dialysis with chromatographic quantification | Parallel assays at pH 5.5 and 7.4, ionic strength reported, zeta tracked | pH and ionic strength must be controlled and reported | Profile shifted entirely by a single pH change |
Recommended IVRT method: dialysis against a medium that contains an albumin or cyclodextrin sink at a concentration justified by drug solubility.
Why it fits: lipophilic drugs dissolve into the lipid phase itself, so release is essentially a partitioning process between particle and medium. Hydrophobic payload encapsulation tends to produce a rapid initial release followed by a slow tail, and the early fraction is often real rather than an artifact.
Key parameters: 0.5-4 % albumin or 1-10 mM cyclodextrin in PBS, large acceptor volume, 37 °C, sampling at 0.25, 0.5, 1, 2, 4, 8, 24, and 48 h.
Watch out for: sink conditions are decisive. If the medium cannot dissolve the released drug, the measured concentration plateaus for thermodynamic reasons, not because the particle is holding on. A solubilizer can also extract drug from the particle, so its concentration must be justified.
Recommended IVRT method: sample-and-separate with ultrafiltration, taking the first aliquot within 1-5 minutes to capture the burst.
Why it fits: hydrophilic drugs reside in the aqueous core or in channels within the lipid matrix and diffuse out quickly. Release is fast and often nearly complete, which makes the assay easy but the sampling demanding. Hydrophilic payload encapsulation studies therefore need early time points and a fast separation step.
Key parameters: PBS at pH 7.4, ultrafiltration with a cut-off well below particle size, low-binding tubes, samples at 1, 5, 15, 30, 60, and 120 min.
Watch out for: if the first aliquot is taken at thirty minutes, the most informative part of the curve has passed. A nearly complete, very fast release is not automatically a failure — for some applications a rapid release is intended, and the assay simply confirms it.
Recommended IVRT method: dual-pH dialysis running parallel assays at pH 5.5 and 7.4, with chromatographic quantification and zeta-potential tracking.
Why it fits: for drugs that carry a charge at physiological pH, release depends on the ionization state and on how strongly the molecule associates with the lipid. Because the ionizable lipid responds to the same pH, the two effects are coupled, and the profile can change substantially between pH 5.5 and pH 7.4. The broader design space is covered under LNP small-molecule delivery.
Key parameters: parallel assays at pH 5.5 and pH 7.4, matched ionic strength across both, a validated HPLC or LC-MS readout, and zeta-potential tracking at the start and end of the assay.
Watch out for: a single-pH assay is insufficient when charge dominates. Tracking surface charge with nanoparticle surface charge analysis explains why a profile shifts, since a change in zeta potential is direct evidence that the surface is changing.
Sink conditions, solubilizer choice, and pH often explain more than the formulation does. BOC Sciences helps design a medium and separation scheme that reports the true release of your small-molecule payload.
Combination payloads are increasingly common because one particle can deliver two agents that act together. Co-loading, however, multiplies the analytical challenge: release must be resolved for each component, and the two profiles may not track each other at all. The table below maps each co-loading combination to its recommended IVRT method.
Table 6. Recommended IVRT Methods for Co-Loaded LNPs
| Combination | Recommended IVRT Method | Analytical Requirement | Key Parameters | Practical Approach |
| Two nucleic acids | Dialysis with length-selective readout | Resolve two polyanions of different length in the same sample | MWCO 300-1000 kDa, capillary electrophoresis or gel readout, length-selective detection | Size- or charge-based separation with a length-selective readout |
| Nucleic acid plus small molecule | Dual-readout dialysis and HPLC | Two chemically unrelated species with different solubilities | Dye-exclusion fluorescence for nucleic acid plus HPLC for drug; matched time points | Orthogonal detection; a fluorescent nucleic acid readout combined with chromatographic drug quantification |
| Nucleic acid plus protein or peptide | Dual-readout sample-and-separate | Preserve protein integrity while tracking a nucleic acid co-cargo | Low centrifugal force, immunoassay for protein, dye-exclusion for nucleic acid | Immunoassay or labeled-protein detection alongside a nucleic acid-specific readout |
Recommended IVRT method: dialysis with a length-selective readout such as capillary electrophoresis or an agarose gel.
Why it fits: when two nucleic acids are carried together, the longer strand usually releases more slowly, so the ratio of the two cargos in the released fraction drifts over time even if both eventually leave. Capturing that drift requires a readout that distinguishes the two species by length rather than total fluorescence.
Key parameters: MWCO 300-1000 kDa, sampling at matched time points for both species, capillary electrophoresis or gel imaging with length-selective quantitation, and a spiked dual-species recovery control.
Watch out for: do not report a single combined fluorescence number. The principles behind co-encapsulation of multiple payloads in LNPs explain why the ratio set at formulation rarely matches the ratio seen during release.
Recommended IVRT method: dual-readout dialysis with a fluorescent nucleic acid assay running in parallel with an HPLC drug quantification.
Why it fits: pairing a nucleic acid with a small molecule combines an electrostatically bound cargo with a partitioning one, so the two release mechanisms are largely independent. That is biologically important: a fast-diffusing drug can leave well before the nucleic acid, changing the intended temporal relationship. Programs pursuing LNP co-delivery report two profiles from one experiment.
Key parameters: dialysis with a sink medium tailored for the small molecule, parallel dye-exclusion and HPLC readouts at every time point, and matched sample volumes across the two assays.
Watch out for: verify both time courses, not just the faster one — a fast-diffusing drug can leave well before the nucleic acid, changing the intended temporal relationship.
Recommended IVRT method: dual-readout sample-and-separate with an immunoassay for the protein and a dye-exclusion assay for the nucleic acid.
Why it fits: here the protein or peptide is the fragile partner, and the assay must avoid conditions that unfold or adsorb it. Because the nucleic acid readout is usually more sensitive, it is tempting to optimize the method for the nucleic acid first; that order should be reversed when the protein drives the effect being studied.
Key parameters: low centrifugal force, low-binding tubes, carrier protein in the collection vial, immunoassay validated against a spiked sample, and matched dye-exclusion time points.
Watch out for: optimize the protein readout first when it drives the biological effect. Add a single-payload particle tested under identical conditions to establish the baseline for each cargo, so any interaction introduced by co-loading becomes visible rather than inferred.
Once the method family is fixed, the release profile is decided by the medium and the operating conditions. These are not secondary details; they frequently decide whether a formulation is judged stable or leaky.
The medium has to be relevant to the environment the particle will meet: a physiological pH, a defined ionic strength, and a protein content that can act as an acceptor for lipophilic cargo. Phosphate-buffered saline is the simplest starting point; a serum-containing medium is more predictive for a lipophilic drug. Where the buffer itself is a variable, LNP buffer screening can identify a composition that keeps both particle and assay stable.
Charge effects: pH and ionic strength modulate both drug ionization and lipid surface charge, so testing more than one pH exposes the mechanism when charge dominates. Measuring zeta potential with nanoparticle zeta potential analysis in the same media confirms comparability across conditions.
Sink conditions mean the released payload dissolves freely in the acceptor phase, so the measured concentration reflects release rather than solubility. For a lipophilic cargo this is rarely automatic, and the fix is to add an acceptor — albumin, a surfactant, or a cyclodextrin — at a concentration justified by the drug's solubility rather than chosen by convenience.
Related concept: how loading capacity and encapsulation efficiency are reported affects how sink conditions are set, and the relationship is described in loading capacity and encapsulation efficiency in LNPs. Where a drug saturates the particle, even a well-designed medium will struggle to keep the acceptor phase undersaturated.
Release testing is usually run at a temperature matching the intended application, with gentle agitation to prevent settling without introducing shear. The sampling schedule matters as much: too few early points and a burst phase is invisible, too few late points and a slow tail is indistinguishable from a plateau.
Practical rule: take at least one point within the first minutes, several points across the first hours, and enough late points to show whether the curve has genuinely stopped rising. Because these choices define what the assay can detect, they belong alongside the attributes tracked through LNP quality attribute testing.
For dialysis-based methods, the molecular weight cut-off must be large enough that the payload crosses freely and small enough that the particle cannot. A cut-off only slightly above the payload size turns the membrane into the rate-limiting step, while an oversized membrane risks leaking intact particles.
Compatibility check: run a membrane-only control with free payload to measure diffusion lag, and test whether the membrane adsorbs the cargo. Optimizing the encapsulation step in parallel, for instance through LNP encapsulation efficiency optimization, also reduces the free-payload background.
Most discrepancies between a release profile and a formulation's real behavior trace back to a small set of recurring problems. Recognizing them early saves both time and misattributed results.
Table 7. Common Challenges in LNP Release Testing and Practical Solutions
| Challenge | Root Cause | How to Address It |
| Membrane adsorption and payload binding | Payload or lipid sticks to the membrane or to vessel surfaces | Add a carrier protein, use low-binding materials, and run a free-payload recovery control |
| Burst release and payload leakage | Surface-associated payload, or a shell that destabilizes over time | Separate surface from core payload; monitor retention during storage and in serum |
| Aggregation and colloidal instability | Ionic strength, pH shifts, or protein interaction during the test | Match the medium to the intended environment and track size and zeta potential throughout |
Adsorption is the most common cause of a release curve that looks artificially low. The payload leaves the particle, contacts the membrane or the vessel wall, and never reaches the analysis. A structured program such as LNP encapsulation troubleshooting starts by quantifying recovery rather than by changing the formulation.
Quick diagnostics: run a spiked free-payload sample through the identical workflow, compare concentrations before and after filtration, and switch to low-binding tubes or add a carrier protein if recovery is incomplete.
Not all early release is a defect. Some payload sits near the surface and leaves as soon as the particle meets the medium, and for many applications that fast fraction is intended. The problem arises when early release is larger than designed or continues during storage. Distinguishing the two requires a retention assay run in parallel with the release assay: LNP payload retention during storage covers shelf life, while LNP payload retention during serum exposure addresses leakage in biological fluid.
Interpretation point: a large surface-associated fraction usually points to the encapsulation process rather than the lipid composition, and often persists across formulation changes until the loading step is adjusted.
A release assay places the particle in a medium it may never encounter during manufacture, and that medium can destabilize the colloid. Aggregation changes the surface area available for release, traps payload inside clumps, and compromises any measurement that assumes a well-dispersed suspension. Lipid nanoparticle stability testing and release testing are therefore most informative when run together.
Controlling the variable: match the ionic strength of the medium to the intended application, avoid abrupt pH jumps during buffer exchange, and confirm the size distribution is unchanged at the end of the assay. Where a batch behaves inconsistently, the causes reviewed in batch reproducibility in scalable LNP production are often a better explanation than an intrinsic release difference.
Adsorption, burst release, and aggregation account for most unexpected profiles. BOC Sciences helps isolate the true cause before you change a formulation that may already be fit for purpose.
A release assay is only as useful as the question it is built to answer. BOC Sciences develops IVRT methods around a defined payload, a defined medium, and a defined decision.
Method development starts from the payload's physicochemical behavior and works toward a separation scheme, a release medium, and a sampling schedule that can resolve the events of interest.
Each payload class needs its own separation and detection strategy, validated against a spiked sample to establish recovery. Support spans nucleic acid dye-exclusion assays, chromatographic separation of free and encapsulated species, and immunoassay detection for biological cargos.
Beyond raw recovery, BOC Sciences helps interpret profiles — fitting release kinetics, assessing a method's ability to discriminate between formulations, and comparing candidates or batches under a consistent protocol. This is supported by nanoparticle characterization testing, with physical measurements including nanoparticle size analysis, nanoparticle morphology characterization, and nanoparticle structural characterization, so a release result can be read together with the structure that produced it. Where surface charge is the variable of interest, LNP zeta potential optimization completes the picture.
Table 8. BOC Sciences Support for Payload-Specific LNP In Vitro Release Testing
| Service | Scope of Service | Key Deliverables | Inquiry |
| IVRT Method Development and Test Condition Optimization | Method family selection, release medium design, sampling schedule, membrane and cut-off selection, control samples | Documented IVRT protocol with recovery data, method parameters, and a suitable medium for the target payload | Inquiry |
| Payload-Specific Release Testing Services | Release testing executed for nucleic acid, protein, peptide, small-molecule, and co-loaded LNP formulations | Complete release profiles with time points, raw data, and a short interpretation of release behavior | Inquiry |
| Free and Encapsulated Payload Separation | Development of separation steps that cleanly resolve free payload from encapsulated payload for quantification | Validated separation with recovery and specificity data across the relevant concentration range | Inquiry |
| Payload Retention Testing | Retention assessment under storage-like and serum-exposure conditions to distinguish design leakage from instability | Retention profiles over time with identification of the surface-associated versus encapsulated fractions | Inquiry |
| Release Profiling and Kinetic Analysis | Profiling of release kinetics, model fitting, and head-to-head comparison of candidate formulations or batches | Ranked formulation comparison with kinetic parameters and a discrimination assessment of the method | Inquiry |
| Drug Loading and Encapsulation Analysis | Simultaneous determination of loading and encapsulation to define the starting state of each release experiment | Loading and encapsulation values with the analytical method and the calculation basis used | Inquiry |
In vitro release testing for lipid nanoparticles is not one method but a family of methods, and the correct choice follows from the payload. Long RNA and plasmid DNA release slowly under electrostatic dissociation, so dialysis with a well-matched membrane remains the reference approach. Short oligonucleotides and small molecules move faster, shifting the emphasis toward separation resolution, sink conditions, and early sampling. Proteins, peptides, and ribonucleoproteins add a structural dimension, where recovery controls and integrity checks are part of the measurement. Co-loaded particles must be profiled component by component, because one combined release number conceals the divergence that matters.
Across every payload class, three parameters decide whether a profile is trustworthy: the release medium, the sink conditions it provides, and the membrane or separation step between particle and detector. For teams working through that design space, BOC Sciences offers integrated support spanning IVRT method development, payload-specific separation and quantification, release profiling and interpretation, and the characterization that puts a release result in context.
